May Hill Capital LLC Purchases Shares of 15,446 Hologic, Inc. (NASDAQ:HOLX)

May Hill Capital LLC purchased a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 15,446 shares of the medical equipment provider’s stock, valued at approximately $1,114,000.

A number of other institutional investors have also modified their holdings of HOLX. Benson Investment Management Company Inc. purchased a new position in Hologic during the fourth quarter valued at approximately $4,832,000. Principal Financial Group Inc. grew its stake in shares of Hologic by 0.6% during the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock worth $19,547,000 after purchasing an additional 1,606 shares during the period. Clean Yield Group increased its holdings in shares of Hologic by 18.9% during the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock valued at $3,291,000 after purchasing an additional 7,266 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Hologic by 2.9% in the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after purchasing an additional 800 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Hologic by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after buying an additional 238,222 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

HOLX has been the subject of a number of analyst reports. Raymond James reiterated an “outperform” rating and issued a $90.00 price objective (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Leerink Partnrs cut shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Finally, Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research report on Monday, February 3rd. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Up 0.7 %

NASDAQ HOLX opened at $61.77 on Tuesday. The business’s fifty day simple moving average is $65.08 and its 200-day simple moving average is $73.11. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The firm has a market cap of $13.86 billion, a PE ratio of 19.49, a P/E/G ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 52 week low of $60.34 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.